BTIG reiterates Buy rating on ORIC Pharmaceuticals, $26 price target

What happened

BTIG reiterated a Buy rating on ORIC Pharmaceuticals stock and kept a $26.00 price target. That target implies 188.9% upside from the October 27 close of $9. ORIC also reported promising early efficacy data, including high confirmed PSA response rates with rinzimetostat in heavily pretreated mCRPC patients.

Confirmed

Global impact / market context

This matters because a Buy rating and $26 target signal that BTIG expects the shares to nearly triple from the $9 close. Strong early patient response data supports the case that rinzimetostat, ORIC's drug candidate, may deliver real clinical benefit, which could draw more investor interest.

Analyst inference

ORIC shares are trading near levels seen before last summer, which BTIG calls an attractive entry point ahead of the MEVPRO-1 readout, a coming trial result. If that readout validates the treatment approach, it could lift share value; if it disappoints, the optimistic target would face doubt.

Analyst inference

What to watch

1. Watch for the imminent MEVPRO-1 readout, which BTIG says could further validate the company's therapeutic approach and drive share value. This trial result is the named near-term catalyst in the analyst note. Confirmed
2. Watch whether ORIC Pharmaceuticals can build on the early efficacy data by turning high confirmed PSA response rates into later-stage trial success, since BTIG frames this data as key support for its Buy rating and $26 target. Proposed
3. Watch whether the shares move back toward the $26 target or fall back toward the $9 close, because the 188.9% implied upside is a wide gap that depends on trial results rather than current sales or profit. Analyst inference

Evidence

• Original source link unavailable